Skip to main content

Table 4 Changes in the safety parameters ALP, AST, ALT, and SC at baseline (at Day 0) and after intervention (at Day 84) in the treatment group, mean ± SD

From: Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial

Parameters

Treatment Group (n = 17)

Treatment Group (n = 17)

p-value*

Day 0

Day 84

 

ALP (U/L)

79.00 ± 2.18

73.65 ± 5.35

0.00014

AST (U/L)

30.00 ± 1.73

27.82 ± 2.60

0.00011

ALT (U/L)

31.41 ± 1.58

29.41 ± 3.52

0.0013

SC (mg/dL)*

17.94 ± 2.16

17.47 ± 2.00

0.15

  1. *Measured as Blood Urea Nitrogen to Serum Creatinine Ratio. ALP: Alkaline Phosphatase; AST: Aspartate Aminotransferase; ALT: Alanine Transaminase; SC Serum Creatinine *two-way ANOVA
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us